| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11369590 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(4 years from now) | |
Locametz is owned by Novartis.
Locametz contains Gallium Ga-68 Gozetotide.
Locametz has a total of 1 drug patent out of which 0 drug patents have expired.
Locametz was authorised for market use on 23 March, 2022.
Locametz is available in powder;intravenous dosage forms.
Locametz can be used as for use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer.
The generics of Locametz are possible to be released after 15 August, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 23, 2025 |
Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient
Market Authorisation Date: 23 March, 2022
Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer
Dosage: POWDER;INTRAVENOUS
LOCAMETZ family patents
